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Cell tracking using multimodal imaging
Mangala Srinivasa, Ignacio Melerob, Eckhart Kaempgenc,
Carl G. Figdora and I. Jolanda M. de Vriesa*
In vivo imaging plays a key role in cell tracking, particularly for the optimization of cellular therapeutics. A recent
trend is to use more than one imaging modality (multimodality imaging) for this purpose. There are several advan-
tages to multimodal cell tracking, particularly the corroboration of data obtained using a new imaging agent or
technique with an established one, and the ability to glean complementary information from a single experiment.
In this review, we examine the different types of labels and imaging strategies used in the literature for multimodal
cell tracking, and discuss the pros and cons of these approaches, with a focus on MRI. Despite many efforts and novel
technologies, we still have to face situations where current imaging methods are simply not sensitive enough and
new labeling strategies are hampered by the lack of approved reagents. Finally, we examine new in vitro and preclin-
ical developments, which have the potential to tackle unresolved challenges in in vivo multimodal imaging.
Copyright © 2013 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Multimodal imaging is the use of more than one imaging modality
for a speciﬁc purpose, in this case, cell tracking. Cell tracking
consists of following speciﬁc cells in vivo; this is often in terms of
their localization, but can also be in terms of their fate, functionality
or differentiation. Cell tracking using imaging has several advan-
tages, such as the noninvasive nature of imaging which can allow
longitudinal follow-up of cells, and the ability to acquire speciﬁc
information such as about the numbers of cells in a region of
interest, their viability and their functionality. Noninvasive imaging
is also applicable to humans. For all these reasons, imaging plays a
key role in the optimization of cellular therapeutics (1). Multimodal
imaging is particularly powerful in that it allows for comprehensive
monitoring of labeled cells, as the strengths of the different
imaging modalities can be maximized. Multimodal imaging can
be done using a single label or tracer that is visible using different
imaging modalities, or a combination of imaging labels. The imag-
ingmodalities typically applied to cell tracking include whole body
scintigraphy, magnetic resonance imaging (MRI), positron
emission tomography (PET), ﬂuorescence imaging (FLI), biolumi-
nescence (BLI) and single photo emission computed tomography
(SPECT).
SPECT, PET and scintigraphy require the use of radioactive
labels. For example, SPECT and scintigraphy are commonly done
using 111In and 99mTc. These have half-lives of up to 3 days,
dependent on the isotope. PET tracers, often 18 F analogs of
glucose or thymidine, are much more short-lived, with half-lives
in the order of hours. Furthermore, all these agents result in radi-
ation exposure to subjects and thus their dosage and repeated
use is limited and tightly regulated. However, nuclear medicine
imaging techniques such as these can be very sensitive and yield
quantitative information on label content. MRI, on the other
hand, does not require the use of radiolabels. Instead, cells are
labeled with iron oxide nano- or microparticles, or other metals
such as gadolinium (Gd) or manganese (Mn). MR imaging works
on the 1H nucleus, present abundantly in biological tissues,
particularly in the form of mobile water, resulting in exquisite
anatomic detail. Contrast agents result in the labeled cells
presenting as hyperintense (T1 agents) or hypointense regions
(T2 and T2
* agents) on appropriately weighted MR images.
Imaging using certain iron oxide agents can be very sensitive,
even up to single cell imaging (2). Note that the use of MR con-
trast agents is also closely regulated, and they are not ofﬁcially
approved as cell labels. MR reporter genes have also been devel-
oped, where the genes are typically involved in intracellular iron
levels (3). However, quantiﬁcation of cell numbers with contrast
agents can be difﬁcult. Recently, much work has focused on
labeling cells with 19 F agents for cell tracking. 19 F MRI is quanti-
tative, but suffers from sensitivity issues and is still in preclinical
testing (4). Finally, the light-based in vivo imaging modalities,
FLI and BLI, are perhaps the most common owing to their
relative ease of use. However, the techniques are limited by
the penetration depth of light, and are thus most often used in
preclinical models, particularly nude mice, with limited potential
for translational application to humans. The use of ﬂuorescent
agents to label cells is very well established, for example in
microscopy and ﬂow cytometry. For these reasons, ﬂuorescent
agents are most often combined with imaging agents for MRI,
SPECT or PET. BLI is similar to FLI, except that it requires the
expression of an enzyme, luciferase, which catalyzes the
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conversion of a substrate (luciferin to oxyluciferin) with the
release of a photon. The photon released is detected. Typically,
cells express luﬁcerase as a reporter gene and luciferin is injected
intravenously. Thus, this technique requires that the relevant
cells be viable for imaging, not simply the presence of label.
Reporter genes can also be used to label cells for PET imaging
where a 18 F-labeled precursor is metabolized and retained by
the gene-expressing cells (5).
2. ROLE OF MULTIMODAL IMAGING
2.1. Validation
One of the main advantages of multimodal imaging is that an
established imaging modality or technique can be combined
with a more experimental one. Typically FLI and ﬂuorescence-
based techniques, such as microscopy, histology and ﬂow cytom-
etry, function as the established modality and can be considered
the gold standard. Fluorescent dyes are well-characterized and
relatively easy to add to imaging agents, for example, simply
dissolved in a surfactant with liposomal agents or covalently
bound to particulate agents. Alternatively, some studies use
transgenic cells that express a ﬂuorescent protein, or luciferase
for BLI or a reporter enzyme for PET. These can be constitutionally
expressed or used as a reporter gene for a given biofunction. In
either case, luminescence indicates live and functional cells, and
not simply the presence of imaging label, when the expressed
luciferase is ATP-dependent. A recent example demonstrated
the power of this combination (18): mesenchymal stem cells were
transfected with a luciferase vector and labeled with either
superparamagnetic iron oxide (SPIO) or Gd for MRI. The authors
found that SPIO signal persisted even after complete loss of BLI
signal. SPIO signal persisted longer than Gd signal. This demon-
strates that simply the presence or absence of signal owing to a
contrast agentmay not indicate live cells. Often, dead cells and their
material (including some imaging agents) can be phagocytosed by
macrophages and thus indirectly label these cells. These factors
must be taken into account when interpreting in vivo image data.
2.2. Complementary Information
The use of another scientiﬁc technique, with a more established
label and protocol, is essential to develop and apply a new label
and/or imaging modality. For example, histology or microscopy
Figure 1. Multimodal imaging of labeled human islets. The islets were labeled with a ﬂuorinated emulsion, where the ﬂuorocarbon used also contains a Br atom
which allows for Computed Topography (CT) contrast. (a) Shows 1H MRI detection of iron-labeled islets, at 50 islets/ml gel. The dark spots represent single islets
(inset). (b) CT image of 10 ﬂuorine-labeled islets. (c) 19 F MR imaging of labeled ﬂuorine-labeled islets, with a phantom containing 10, 50, 100 and 200 islets at high
ﬁeld strength. (d) Lower ﬁeld strength imaging of ﬂuorine-labeled isletswith 500, 1000, 2000, 3000 and 4000μgof ﬂuorocarbon (top), and 500, 1000, 1500, 2000 and
2500 ﬂuorine-labeled islets (bottom). (e) Ultrasound images of ﬂuorine-labeled islets in a phantom with 10, 50, 100 and 200 islets. (f) In vivo ultrasound images of
ﬂuorine-labeled islets transplanted intramuscularly in a nudemouse, at 1, 5 10 and 25 islets per injection. Figure reproduced from Barnett et al. (7), with permission.
M. SRINIVAS ET AL.
wileyonlinelibrary.com/journal/cmmi Copyright © 2013 John Wiley & Sons, Ltd. Contrast Media Mol. Imaging 2013, 8 432–438
434
has often been used as the ‘established’ technique to conﬁrm
in vivo image data. Histology can only be performed at the end-
point of an in vivo study, and is thus often supplemented or even
replaced by FLI. Thus, most preclinical imaging agents contain a
ﬂuorescent component. Confocal microscopy is also typically
used to study intracellular localization, although this can also
be done with electron microscopy with agents such as iron
oxides or quantum dots.
Other combinations of imaging modalities are used to yield dif-
ferent types of information. For example, MRI can be used for lo-
calization, together with scintigraphy or SPECT for quantiﬁcation
of cells labeled with both SPIO and radioactive indium isotopes.
This has been done clinically to track dendritic cells in melanoma
patients (19). More recently, such trials have been combined with
PET, as PET can give longitudinal data on cell functionality (20).
The ability of multimodal imaging to yield complementary
information is exempliﬁed in a protocol designed to study stem
cell implantation (11); BLI was used to assess cell survival, MRI for
localization and post-mortem histology to validate the in vivo
imaging results. In this example, the cells and the MRI label both
had different ﬂuorescent dyes to allow exact localization of the
MRI agent using microscopy.
2.3. Labeling Strategies
Multimodal imaging requires that cells are labeled with imaging
agents detectable by more than one imaging modality. However,
this canmean a single agent, or a combination of chemically distinct
agents in a cell or a combination of tracing cells that are individu-
ally labeled for a single imaging modality (see graphical abstract).
All of these combinations have been used in the literature.
Table 1. Representative list of the different combinations of in vivo multimodal imaging for cell tracking used in the literature.
Agent refers to the type of label used, for example, liposomes or molecular constructs
Agent Cell type Imaging modalities Reference
Reporter gene Transfected tumor cell FLI, MRI, PET (6)
Emulsion Pancreatic islets FLI, MRI, CT, ultrasound (7)
Gold nanoparticles, Gd chelates Pancreatic islets MRI, CT, US (8)
Iron oxide, PET tracer Stem cells MRI, PET (9)
MicroRNA-targeted magnetic
ﬂuorescence nanoparticles
Neuronal stem cells MRI, FLI (10)
eGFP and luciferase expressing cells
labeled with iron oxide
Transgenic murine stromal cells FLI, BLI, MRI (11)
SPIO conjugated to 111In Tumor cell line MRI, SPECT (12)
Functionalized silica nanoparticles Immune cells FLI, MRI, PET (13)
PEGylated complex Stem cells MRI, luminescence (14)
Molecular complex MRI, CT, luminescence (15)
Particles BLI, PET, MRI, FLI (16)
Antibodies BLI, scintigrapy (17)
MRI, magnetic resonance imaging; PET, positron emission tomography; FLI, ﬂuorescence imaging; BLI, bioluminescence; SPECT,
single photo emission computed tomography.
Table 2. A general summary of the main issues that arise with multimodal imaging for cell tracking, and their common solutions
Issue Solution
Imaging often detects only the
presence of label, whether or not it is in the relevant cells
Reporter genes, or coupling to a second
imaging agent that is known to be cell-speciﬁc
Effect of label on cells, particularly long-lived cells More extensive testing of labeled cells,
including speciﬁc functionality assays
Difﬁculties in image registration with different imaging modalities,
particularly with deformable tissues
Various strategies have been developed,
such as subject immobilization, addition of references,
computer algorithms, and the use of hybrid scanners
Cost and increased imaging time The introduction of hybrid scanners can reduce
imaging time and cost
Discrepancy between data from different imaging modalities These typically arise owing to differences in
sensitivity to cell viability or functionality
between the labels
Multiple and longer imaging sessions, and increased and
more frequent use of anesthetics in preclinical studies
Hybrid scanners where possible, and
careful planning is necessary
Complex anatomy and organ movement (bone, bone marrow,
lymph nodes, heart, lung)
Speciﬁc adjustments and data processing
for recording and overlaying data.
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When a combination of cells with individual labels is used, it is
assumed that the cells will colocalize and that the different labels
do not affect the cells differently. Furthermore, it is possible that
label is not taken up uniformly within a cell population, generat-
ing mixed results in viability or functionality assays (21), and the
possibility that the image data does not reﬂect the behavior of
the majority of nonlabeled cells. Lastly, inadvertent label transfer
may occur to nonrelevant cells.
A ﬁnal factor that can affect image interpretation is the dilu-
tion of label with cell division. This will not occur if the cells are
labeled in situ, or if a reporter gene is used. However, even with
rapidly dividing cells, the number of cell divisions that occur may
result in tolerable quantiﬁcation errors (22). All of these issues
must be considered when designing the experimental model.
2.4. Effects on Cells
A recent paper (23) discussed the confounding effect that the sim-
ple addition of biomaterials, such as contrast agent nanoparticles,
can have on standard cytotoxicity assays. This effect occurs owing
to the formation of a coating of biomolecules, particularly proteins,
on the nanoparticle surface (24), signiﬁcantly altering the cell
medium. The simple aggregation and sinking of label particles
can also affect the actual concentration to which the cells are
exposed. Other key factors that must be considered are the life-
time of the cell vs the lifetime of the label, viability, in vivo toxicity
and clearance and speciﬁc effects on cell functionality. Most often
the concentration of label added to cells is selected to balance any
effects on the cell with maximal label loading.
In addition to the general effects of adding agents, particularly
nanoparticles, to cells, speciﬁc functional effects can also occur.
Several studies have looked into the effect of labeling various cell
types with iron oxide agents for MRI, with mixed results on cell vi-
ability and functionality. For example, labeling human embryonic
stem cells with SPIO had no effect on pluripotency or differentia-
tion capacity compared with nonlabeled controls (25). In this study
the amount of iron loading was about 4.5pg/cell, which is a typical
value although the authors used a shorter incubation time and
lower SPIO concentration when labeling. The label persisted for
21 days in the cells. Other studies found that labeling with SPIO af-
fected the insulin synthesis in a pancreatic cell line (26), cytokine
secretion in macrophages (27) and mobility of neural stem cells
(28,29). However, the majority of published data show minimal or
no signiﬁcant effects of labeling with iron oxide on cells, at least
on standard assays.
With other imaging modalities, particularly SPECT and PET, the
effects of radiation from the agent must also be considered,
particularly when labeling long-lived cells such as stem cells
(30,31). This is in addition to limitations in the detection time
frame owing to the radioactive half-life of the isotope used.
2.5. Multimodal Imaging in Cellular Therapy
The role of imaging in cellular therapy has been reviewed
elsewhere (1). Clinical cell tracking has generally been done using
scintigraphy and SPECT, and more recently with MRI using
iron-based labels, although this may be hindered by the recent
removal of several MRI contrast agents from the market. FLI, which
is the most commonly used ‘second’ imaging modality in the
preclinical world, has limited applicability in humans owing to
penetration depth issues. Furthermore, increased cost, imaging
time, toxicity and side-effects, the need for more trained personnel
and simply the novelty of the techniques has somewhat limited
the use of multimodal imaging in clinical cellular therapy.
However, the multitude of preclinical studies now available
has demonstrated the necessity for multimodal imaging in opti-
mizing cellular therapy, especially as the ﬁeld of cellular therapy
itself develops and becomes more complex. Figure 1 shows an
example of a multimodal imaging of labeled pancreatic islets.
3. CONSIDERATIONS
Several assumptions are typically made when imaging labeled
cells for in vivo imaging. These are summarized in Table 1, along
with the most common strategies used to counter them.
Some agents have been developed and shown to be chemi-
cally feasible but have not been tested in vivo or even in cells
(see Table 2 for examples). Such testing is especially important
when the agents contain heavy metals, which are extremely
toxic if released from stabilizing chelates. For example, Gd
chelates, commonly used as blood pool agents for MRI contrast,
are now indicated as a risk factor for systemic nephrogenic ﬁbro-
sis (32). Carbon nanotubes and silica nanoparticles, both of
which show great promise as preclinical imaging agents, may
also have issues owing to long retention times (33).
4. SUMMARY AND OUTLOOK
The use of reporter genes revolutionized ﬂuorescence
microscopy, as it allows the production of reporters such as a
ﬂuorescent protein linked to another gene product or constitu-
tively expressed. Thus, the presence of the reporter product is
highly restricted to a speciﬁc cell type, is not diluted by cell
division (if the gene becomes integrated) and occurs only in
viable cells. Luciferase is typically used as a reporter gene
product for BLI, and reporter genes have also been developed
for MRI. These reporters are typically proteins involved in cellu-
lar metal homeostatis, particularly iron storage (34). A recent
study used the expression of a metabolically biotinylated
luciferase that is membrane bound (6). This construct allowed
in vivo BLI, and also targeting of other imaging agents to the
membrane-bound biotin using streptavidin-bound Alexa750
(FLI), 111In (SPECT) and magnetic nanoparticles (MRI). This
approach couples targeting and noninvasive imaging. Such an
approach is easily amenable to multimodal imaging, but is
restricted to genetically modiﬁed cells and subjects on biotin-
deﬁcient diets. The use of reporter genes for imaging may
overcome some of the disadvantages of conventional labels,
at least in preclinical models.
It is vital to consider what information is required from the
images (localization, viability, functionality or quantiﬁcation) in
order to determine which imaging modality would be most
applicable, and if multimodal imaging provides relevant, non-
redundant information. The practicality of an imaging scheme
must also be considered, in terms of the number of imaging
sessions required, cost, imaging time and (repeated, frequent)
anesthetic use for preclinical studies. A multimodal imaging
study can yield more information per subject, but requires more
and longer imaging sessions per subject. For example, simply
organizing the logistics can become difﬁcult: in one paper
(20), patients received injections of a radioactive tracer for PET
after receiving cellular therapy for cancer. The PET tracer
M. SRINIVAS ET AL.
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accumulated in treated lymph nodes, but this presented new
problems as some of these patients were also scheduled for
lymph node resections, thus potentially exposing the surgical
staff to the residual radioactivity. Furthermore, the PET tracer
itself had to be prepared and transported from the cyclotron
in time for the cell injections, within the usable lifetime of the
tracer. These kinds of studies require precise and thorough
planning, and can involve over 50 people in the clinic. Despite
these issues, PET is a common clinical imaging modality that is
now more often being combined with MRI (and has long been
combined with CT).
Finally, the addition of speciﬁc functionalities to multimodal
imaging agents is under development. For example, one agent
consists of a iron oxide core with quantum dots functionalized
with an anti-cancer agent and a targeting motif (35). In this agent,
the quantum dots remain quenched until activated by speciﬁc in-
tracellular reactions triggered by drug uptake. Overall, despite
the feasibility challenges, in our opinion, multimodal imaging will
offer many advantages to guide progress in cellular therapeutics.
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